InVitae Compares NGS Assay for Determining Hereditary Cancer Risk to Myriad's BRACAnalysis | GenomeWeb

NEW YORK (GenomeWeb) — Genetic testing company InVitae has evaluated the clinical performance of a next-generation sequencing-based test for determining hereditary cancer risk and found that it is as good as Myriad Genetics' BRACAnalysis test at identifying variants in the BRCA genes and can also find additional variants that increase the risk of hereditary cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.